17
Sep
2024
Sickle Cell Patient Cured With CRISPR Summits Kilimanjaro, Setting World Record
Four years after being functionally cured of sickle cell disease with a CRISPR gene-editing therapy, Jimi Olaghere has set a new world record for patients with this chronic and deadly disease. Olaghere, a 39-year-old business owner from Atlanta, became the world’s first patient with sickle cell disease to reach the summit of Kilimanjaro at 7:30 am Tanzania time on Sept.... Read More
10
Sep
2024
Amy Abernethy, Brad Hirsch Aim for Better Medical Evidence With Highlander Health
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Sep
2024
Candid Therapeutics Emerges with $370M to Develop T-Cell Engagers for Autoimmunity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Sep
2024
The Enchantments Traverse: A Photo Gallery
The 4th annual Timmerman Traverse for Life Science Cares wrapped up last month, but I’m feeling a bit remiss for not telling the whole story. This year’s successful $1 million campaign came in two parts. First, there were a pair of back-to-back day hikes in the North Cascades with a team composed mostly of newcomers to the Life Science Cares... Read More
5
Sep
2024
Raising the Bar for Sickle Cell Patients: Ted Love and Alan Anderson on The Long Run
Today’s guests on The Long Run are Ted Love and Alan Anderson. Ted is the chairman of the board of directors at the Biotechnology Innovation Organization. He’s perhaps best known for serving as CEO of Global Blood Therapeutics, the San Francisco Bay Area company that developed voxelotor (marketed as Oxbryta), a novel small molecule for sickle cell disease. The company... Read More
4
Sep
2024
Arsenal Bio Fetches $325M To Make CAR-T Therapies for Solid Tumors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Aug
2024
Timmerman Traverse for Life Science Cares Hits $1M Goal to Fight Poverty
We did it! The Timmerman Traverse for Life Science Cares wrapped up last week. This team of biotech executives and investors hit its goal of raising $1 million to fight poverty in the United States. We hiked about 20 miles together, gaining between 6,000 and 8,000 vertical feet of elevation in the North Cascades of Washington state. This trip had... Read More
14
Aug
2024
RNA Medicines to Treat Muscle Diseases: Sarah Boyce on The Long Run
Today’s guest on The Long Run is Sarah Boyce. She is the CEO of San Diego-based Avidity Biosciences. Avidity is a developer of RNA medicines. It uses what it calls “antibody oligonucleotide conjugates”. These are molecules that connect an antibody — which hits a specific target on the surface of cells – with an RNA-silencing molecule. That RNA molecule can... Read More
8
Aug
2024
Recursion Scoops up Rival, Servier’s Brain Cancer Win, & Cell Therapy for Solid Tumors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jul
2024
PBMs Feel the Heat, Megarounds Abound, and the XBI Tops 100
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jul
2024
Biologic Drug Discovery With AI: Sean McClain on The Long Run
Sean McClain is today’s guest on The Long Run. He’s the founder and CEO of Vancouver, Washington-based Absci. Sean started the company on his own in his early 20s, straight out of the University of Arizona, with the encouragement of his Dad. You could call it a scrappy garage biotech, with no traditional VC backers at first. He found a... Read More
11
Jul
2024
Lilly Buys Morphic, Flagship Dreams Big, and Element Challenges Illumina
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Jun
2024
A Long-Lasting Drug Against Flu: Jeff Stein on The Long Run
Jeff Stein is today’s guest on The Long Run. He’s the CEO of San Diego-based Cidara Therapeutics. Jeff has led teams that have successfully developed a novel antibiotic, and a novel antifungal, all the way through FDA approval. This latest project with an antiviral could be the most important of his career. Cidara has a platform for making drug-Fc conjugate... Read More
25
Jun
2024
Exsilio Gets $82M to Make mRNA Therapies That Integrate and Endure
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jun
2024
On Juneteenth, Recognizing 18 Black Biopharma Industry Leaders
Ken Frazier, Tony Coles, Rob Perez and Ted Love are among the biggest names in the biopharma industry. They also happen to be Black. But there are many other Black people making significant contributions, and who aren’t so widely known. Let’s recognize some of these folks today on the Juneteenth holiday. On June 19, 1865 — long after the Emancipation... Read More
18
Jun
2024
Marea, Incubated by Third Rock, Gets $190M to Take Aim at Remnant Cholesterol
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jun
2024
Precision Neuroscience for Epilepsy and More: Abe Ceesay on The Long Run
Abe Ceesay is today’s guest on The Long Run. He’s the CEO of Boston-based Rapport Therapeutics. Rapport started with a $100 million Series A financing in March 2023 from Third Rock Ventures, Arch Venture Partners and Johnson & Johnson Innovation. As the company name subtly suggests, it’s based on biology of R A Ps, or receptor-associated proteins. The idea is... Read More
13
Jun
2024
Avidity Delivers, Foresite Raises $900M, & Lilly Alzheimer’s Drug Passes Scrutiny
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jun
2024
Santa Ana Bio Debuts with $168M to Develop Precision Inflammatory Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Jun
2024
AstraZeneca’s Big ASCO, Summit Breaks Out, & Structure’s Oral GLP-1 Advance
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.